MultiCell Technologies Inc (MCET)

[redsox17]

PR Newswire

PUNE, India, May 19, 2016

PUNE, India, May 19, 2016 /PRNewswire/ --

ReportsnReports.com adds "Hepatitis C - Pipeline Review, H1 2016" to its store. The report provides an overview of the Hepatitis C's therapeutic pipeline with comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects.

Complete report on H1 2016 pipeline review of Hepatitis C with 154 market data tables and 17 figures, spread across 585 pages is available at http://www.reportsnreports.com/reports/543633-hepatitis-c-pipeline-review-h1-2016.html .

The report also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Companies discussed in this Hepatitis C Pipeline Review, H1 2016 report include 3-V Biosciences, Inc., AbbVie Inc., AiCuris GmbH & Co. KG, AIMM Therapeutics B.V., Akshaya Bio Inc., Altor BioScience Corporation, Amarillo Biosciences, Inc., Amarna Therapeutics B.V., ARA Healthcare Pvt. Ltd., Arbutus Biopharma Corporation, Beijing Kawin Technology Share-Holding Co., Ltd., Benitec Biopharma Limited, BIOCAD, Biogenomics Limited, BioLineRx, Ltd., Bionor Pharma ASA, Biota Pharmaceuticals, Inc., Biotest AG, Biotron Limited, Boehringer Ingelheim GmbH, Bolder Biotechnology, Inc., Bristol-Myers Squibb Company, Celgene Corporation, Chugai Pharmaceutical Co., Ltd., Cocrystal Pharma, Inc., Conatus Pharmaceuticals Inc., DEKK-TEC, Inc., Delpor, Inc., Digna Biotech, S.L., DiscoveryBiomed, Inc., Enanta Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Formune S.L., Genecode AS, GeneCure LLC, Gilead Sciences, Inc., GinkgoPharma Co. Ltd., GlaxoSmithKline Plc, HanAll Biopharma Co., Ltd., HEC Pharm Co., Ltd., Hepacyl Therapeutics, SL, ImmunoBiology Limited, Immunocore Limited, Immunomedics, Inc., Inovio Pharmaceuticals, Inc., Integrated BioTherapeutics, Inc., iTherX, Inc., JN-International Medical Corporation, Johnson & Johnson, Karyopharm Therapeutics, Inc., Kineta, Inc., LG Life Science LTD., Ligand Pharmaceuticals, Inc., Medivir AB, Merck & Co., Inc., Microbio Co., Ltd., Microbiotix, Inc., ]MultiCell Technologies, Inc., Novartis AG, NovaTarg Therapeutics, Inc, Ono Pharmaceutical Co., Ltd., Pfenex Inc., Pfizer Inc., PharmaEssentia Corporation, Polaris Pharmaceuticals, Inc., Presidio Pharmaceuticals, Inc., Profectus BioSciences, Inc., Regulus Therapeutics Inc., Rodos BioTarget GmbH, Savoy Pharmaceuticals, Inc., SEEK Group, SomaGenics, Inc., Sorrento Therapeutics, Inc., Spring Bank Pharmaceuticals, Inc., TaiGen Biotechnology Co., Ltd., TaiwanJ Pharmaceuticals Co., Ltd., TGV-Laboratories, Therapix Biosciences Ltd, Therapure Biopharma Inc., Theravectys SA, Vakzine Projekt Management GmbH, VBI Vaccines Inc., Vertex Pharmaceuticals Incorporated and WhanIn Pharmaceutical Co., Ltd.

Order a copy of Hepatitis C - Pipeline Review, H1 2016 market research report @ http://www.reportsnreports.com/Purchase.aspx?name=543633 .

Scope of this report: The report provides a snapshot of the global therapeutic landscape of Hepatitis C and reviews pipeline therapeutics for Hepatitis C by companies and universities/research institutes based on information derived from company and industry-specific sources and key players involved Hepatitis C therapeutics and enlists all their major and minor projects. The research covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities and assesses Hepatitis C therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects with latest news related to pipeline therapeutics for Hepatitis C.

Another newly published market research report titled on Hepatitis D - Pipeline Review, H1 2016 provides comprehensive information on the therapeutic development for Hepatitis D, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis D and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies discussed in this research are Alnylam Pharmaceuticals, Inc., BioDiem Ltd, Eiger BioPharmaceuticals, Inc., Globeimmune, Inc., REPLICor Inc., SomaGenics, Inc. and Spring Bank Pharmaceuticals, Inc. Hepatitis D Pipeline market research report of 61 pages is available at http://www.reportsnreports.com/reports/543663-hepatitis-d-pipeline-review-h1-2016.html .

Explore more reports on Pharmaceuticals.

About Us:

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441
[e-mail]


Connect With Us on:

Facebook: https://www.facebook.com/ReportsnReports/

LinkedIn: https://www.linkedin.com/company/reportsnreports

Twitter: https: //twitter.com/marketsreports

G+ / Google Plus: https://plus.google.com/111656568937629536321/posts

RSS/Feeds: http://www.reportsnreports.com/feed/l-latestreports.xml

SOURCE ReportsnReports
PR Newswire
www.prnewswire.com


Last updated on: 19/05/2016


More: http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=168012#.Vz21HI-cHcs#ixzz496cvEyS2